Beverly Hills, CA, United States of America

Michelle Lobel

This inventor holds 7 USPTO granted patents and 5 published patent applications. Top assignee: Bryn Pharma, LLC. Active years: 2020-2025.

USPTO Granted Patents = 7 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Michelle Lobel: Innovator in Epinephrine Spray Formulations

Introduction

Michelle Lobel is a prominent inventor based in Beverly Hills, CA. She has made significant contributions to the field of medical formulations, particularly in the development of epinephrine spray formulations. With a total of 7 patents to her name, Lobel is recognized for her innovative approaches to treating anaphylaxis.

Latest Patents

Lobel's latest patents focus on epinephrine spray formulations. These formulations are designed to provide effective treatment for individuals experiencing anaphylaxis. The methods outlined in her patents detail the administration of these spray formulations to subjects in need of urgent medical intervention.

Career Highlights

Throughout her career, Lobel has demonstrated a commitment to advancing medical technology. Her work at Bryn Pharma, LLC has positioned her as a key player in the development of life-saving treatments. Her innovative spirit and dedication to improving patient outcomes are evident in her patent portfolio.

Collaborations

Lobel collaborates with talented professionals in her field, including Steven Hartman and Matthew P Robben. These partnerships enhance her research and development efforts, contributing to the success of her projects.

Conclusion

Michelle Lobel's contributions to the field of epinephrine spray formulations highlight her role as an influential inventor. Her work not only showcases her innovative capabilities but also emphasizes the importance of advancements in medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…